Where Does Wall Street Think Jasper Therapeutics Inc (JSPR) Stock Will Go?

InvestorsObserver is giving Jasper Therapeutics Inc (JSPR) an Analyst Rating Rank of 74, meaning JSPR is ranked higher by analysts than 74% of stocks. The average price target for JSPR is $20 and analyst’s rate the stock as a Strong Buy.

Wall Street analysts are rating JSPR a Strong Buy today. Find out what this means to you and get the rest of the rankings on JSPR!

See Full JSPR Report

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Jasper Therapeutics Inc Stock Today?

Jasper Therapeutics Inc (JSPR) stock has fallen -1.26% while the S&P 500 is higher by 0.36% as of 11:15 AM on Tuesday, Nov 2. JSPR is down -$0.12 from the previous closing price of $9.55 on volume of 146,108 shares. Over the past year the S&P 500 is higher by 39.87% while JSPR is down -4.36%. JSPR lost -$0.34 per share the over the last 12 months. Click Here to get the full Stock Report for Jasper Therapeutics Inc stock.